<DOC>
	<DOC>NCT00536913</DOC>
	<brief_summary>The purpose of the study is to compare Symbicort pMDI with and without spacer in terms of steroid potency, improvement of lung function and asthma symptoms in children with asthma (6-11 years).</brief_summary>
	<brief_title>Evaluation of Safety and Efficacy of SymbicortÂ® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>children 611 years, diagnosed asthma treated 6 months, PEF 50% of predicted normal value prebronchodilator current systemic glucocorticosteroids usage current respiratory infection any significant disease or disorder as judged by investigator</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Symbicort pMDI</keyword>
	<keyword>spacer</keyword>
	<keyword>children</keyword>
</DOC>